Reduction of nocturnal rise in bone resorption by subcutaneous GLP-2.
We have previously shown that a subcutaneous injection of glucagon-like peptide-2 (GLP-2) at 9 a.m. in fasting postmenopausal women results in a dose-dependent decrease in the serum concentration of fragments derived from the degradation of the C-terminal telopeptide region of collagen type I (s-CTX), a marker of bone resorption. In contrast, GLP-2 was found to have a neutral effect on bone formation, as assessed by serum osteocalcin. Since increased s-CTX levels are normally observed at night, we conducted bedtime studies in healthy postmenopausal women. The objective was to study the effect of GLP-2 injection on bone turnover given at bedtime. A total of 81 postmenopausal women were included in two randomised placebo-controlled studies. In conclusion, we found a dose-related reduction of s-CTX after injection of GLP-2 (P < 0.05) and osteocalcin levels was increased as compared to placebo (P = 0.07) by the treatment, suggestive of a stimulative effect on bone formation. An area under the curve (AUC0-10 h) analysis for s-CTX after GLP-2 injection confirmed the dose-related decrease as compared to placebo (P < 0.05).
Henriksen
Dennis B
DB
Nordic Bioscience, Herlev Hovedgade 207, DK-2730 Herlev, Denmark. dbh@nordicbioscience.com
Alexandersen
Peter
P
Byrjalsen
Inger
I
Hartmann
Bolette
B
Bone
Henry G
HG
Christiansen
Claus
C
Holst
Jens Juul
JJ
D001862:Bone Resorption; D024042:Collagen Type I / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D005260:Female; D053767:Glucagon-Like Peptide 2; D004763:Glucagon-Like Peptides; D006801:Humans; D007279:Injections, Subcutaneous; D008875:Middle Aged; D015675:Osteocalcin / Q000097:blood; D010455:Peptides / Q000008:administration & dosage* / Q000097:blood / Q000494:pharmacology*; D017698:Postmenopause
D024042:Collagen Type I; D053767:Glucagon-Like Peptide 2; D010455:Peptides; D015675:Osteocalcin; D004763:Glucagon-Like Peptides